Payment overview · 2025
General Payments
$851.89
38 reported records · 8 companies
Healthcare provider profile · identity verified
German E Crisol, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RIVERSIDE, CA · NPI 1952333650
Verified facts
What the public records show
CMS Open Payments records show German E Crisol, M.D. received $851.89 in general payments during 2025 across 38 reported records.
Amgen Inc. accounted for 44.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $376.82 | 44.2% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $148.34 | 17.4% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.35 | 12.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.04 | 9.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.72 | 6.5% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $38.13 | 4.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.06 | 2.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.43 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $851.89 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $195.54 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $173.05 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $148.34 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102.35 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $88.56 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.72 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $38.13 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
32 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 566 | 182 |
| Metformin Hcl | Metformin Hcl | 231 | 75 |
| Losartan Potassium | Losartan Potassium | 222 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 55 |
| Lisinopril | Lisinopril | 178 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 49 |
| Pioglitazone Hcl | Pioglitazone Hcl | 147 | 50 |
| Omeprazole | Omeprazole | 142 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 45 |
| Gabapentin | Gabapentin | 139 | 51 |
| Alendronate Sodium | Alendronate Sodium | 118 | 42 |
| Januvia | Sitagliptin Phosphate | 118 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 117 | 37 |
| Simvastatin | Simvastatin | 112 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 41 |
| Famotidine | Famotidine | 87 | 36 |
| Ibuprofen | Ibuprofen | 87 | 34 |
| Tramadol Hcl | Tramadol Hcl | 86 | 25 |
| Furosemide | Furosemide | 80 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 22 |
| Xarelto | Rivaroxaban | 72 | 26 |
| Jardiance | Empagliflozin | 68 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 23 |
| Lorazepam | Lorazepam | 59 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 28 |
| Ozempic | Semaglutide | 53 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Ezetimibe | Ezetimibe | 52 | 21 |
| Benazepril Hcl | Benazepril Hcl | 51 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | 16 |
| Farxiga | Dapagliflozin Propanediol | 49 | 15 |
| Alprazolam | Alprazolam | 47 | 13 |
| Carvedilol | Carvedilol | 47 | 16 |
| Eliquis | Apixaban | 47 | 12 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 15 |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Prolia | Denosumab | 32 | 22 |
| Atenolol | Atenolol | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | 11 |
| Myrbetriq | Mirabegron | 28 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 13 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Acarbose | Acarbose | 24 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Piroxicam | Piroxicam | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $851.89 · 38 records | Amgen Inc. | Cologuard Collection Kit, EVENITY, FARXIGA, GEMTESA, JARDIANCE, Kerendia, OTEZLA, Ozempic, REPATHA, Rybelsus, TZIELD, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error